{"id":"levofloxacin-oral-tablets","safety":{"commonSideEffects":[{"rate":"3-9%","effect":"Nausea"},{"rate":"2-5%","effect":"Diarrhea"},{"rate":"2-4%","effect":"Headache"},{"rate":"1-3%","effect":"Insomnia"},{"rate":"<1%","effect":"Tendinitis/tendon rupture"},{"rate":"<1%","effect":"QT prolongation"},{"rate":"<1%","effect":"Photosensitivity"},{"rate":"<1%","effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a fluoroquinolone antibiotic, levofloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA unwinding and replication. This dual inhibition leads to rapid bactericidal activity against a broad spectrum of gram-positive and gram-negative organisms, as well as atypical pathogens.","oneSentence":"Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:54.685Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired pneumonia"},{"name":"Acute bacterial sinusitis"},{"name":"Acute bacterial exacerbation of chronic bronchitis"},{"name":"Uncomplicated skin and skin structure infections"},{"name":"Complicated urinary tract infections"},{"name":"Acute pyelonephritis"},{"name":"Inhalational anthrax (post-exposure prophylaxis and treatment)"}]},"trialDetails":[{"nctId":"NCT06889701","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants","status":"RECRUITING","sponsor":"TenNor Therapeutics Inc.","startDate":"2025-04-03","conditions":"Periprosthetic Joint Infection (PJI)","enrollment":33},{"nctId":"NCT05398679","phase":"PHASE4","title":"Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis","status":"RECRUITING","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-08-17","conditions":"Endocarditis Infective","enrollment":360},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":"HIV Infections","enrollment":1578},{"nctId":"NCT07150065","phase":"PHASE2","title":"Efficacy of Levofloxacin Versus Ciprofloxacin in the Treatment of Childhood Typhoid Fever","status":"COMPLETED","sponsor":"Avicenna Medical College Lahore","startDate":"2025-02-07","conditions":"Typhoid, Fever","enrollment":360},{"nctId":"NCT03479736","phase":"","title":"A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-20","conditions":"Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting","enrollment":117911},{"nctId":"NCT03220074","phase":"PHASE4","title":"Linezolid for Treatment of Nontuberculous Mycobacterial Diseases","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-12-15","conditions":"Non-tuberculous Mycobacterial Infections","enrollment":40},{"nctId":"NCT06684626","phase":"PHASE3","title":"The Role of Butirprost® in Combination With Antibiotics in Chronic Bacterial Prostatitis (CBP) Treatment","status":"COMPLETED","sponsor":"Federico II University","startDate":"2024-03-01","conditions":"Prostate Inflammation, Prostate Disease, Chronic Bacterial Prostatitis","enrollment":60},{"nctId":"NCT04062201","phase":"PHASE3","title":"Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care","status":"COMPLETED","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2019-08-22","conditions":"Tuberculosis, Pre-XDR-TB, Extensively Drug-Resistant Tuberculosis","enrollment":402},{"nctId":"NCT02981615","phase":"PHASE3","title":"Phase 3 Multicenter Randomized Double Blind Placebo Controlled Study With Antibacterial Prophylaxis in Azacitidine Treated MDS Patients","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2017-08-01","conditions":"Prevention","enrollment":67},{"nctId":"NCT06065267","phase":"PHASE4","title":"Levofloxacin Concomitant Versus Levofloxacin Sequential","status":"NOT_YET_RECRUITING","sponsor":"Damascus Hospital","startDate":"2024-01-02","conditions":"Helicobacter Pylori Infection","enrollment":150},{"nctId":"NCT05923021","phase":"NA","title":"Moderate Depressive Disorder With Cheek Acupuncture","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Zhejiang Chinese Medical University","startDate":"2023-07-01","conditions":"Acupuncture, Depression","enrollment":126},{"nctId":"NCT03551210","phase":"PHASE3","title":"Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2016-05-04","conditions":"Pneumonia, Bacterial","enrollment":342},{"nctId":"NCT05306223","phase":"PHASE4","title":"A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China","status":"UNKNOWN","sponsor":"Beijing Chest Hospital","startDate":"2022-05-10","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":212},{"nctId":"NCT00659646","phase":"PHASE2","title":"The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers","status":"COMPLETED","sponsor":"Innocoll","startDate":"2008-04","conditions":"Diabetic Foot Ulcer","enrollment":56},{"nctId":"NCT03201796","phase":"PHASE2","title":"Prulifloxacin in Chronic Bacterial Prostatitis (CBP)","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2016-02-02","conditions":"Chronic Bacterial Prostatitis","enrollment":168},{"nctId":"NCT01988779","phase":"PHASE3","title":"Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations","status":"COMPLETED","sponsor":"University of Rochester","startDate":"2013-10","conditions":"Chronic Rhinosinusitis","enrollment":33},{"nctId":"NCT03697993","phase":"PHASE4","title":"Safety and Efficacy Study of Oral Fosfomycin Versus Oral Levofloxacin to Treat Complicated Urinary Syndromes (FOCUS)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-11-07","conditions":"Urinary Tract Infection","enrollment":62},{"nctId":"NCT03234296","phase":"NA","title":"Antibiotics vs. Placebo in Acute Uncomplicated Appendicitis","status":"ENROLLING_BY_INVITATION","sponsor":"Turku University Hospital","startDate":"2017-08-09","conditions":"Acute Appendicitis","enrollment":147},{"nctId":"NCT02067780","phase":"PHASE3","title":"Short Antibiotic Treatment Versus Duration Guided by Markers of Inflammation in the Treatment of AECOPD","status":"COMPLETED","sponsor":"University of Monastir","startDate":"2017-05-01","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":310},{"nctId":"NCT03757234","phase":"PHASE2","title":"IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis","status":"COMPLETED","sponsor":"Paratek Pharmaceuticals Inc","startDate":"2018-11-19","conditions":"Acute Pyelonephritis","enrollment":201},{"nctId":"NCT03159845","phase":"PHASE2","title":"Zinc as Enhancer in Immune Recovery After Stem Cell Transplantation for Hematological Malignancies","status":"COMPLETED","sponsor":"Azienda Ospedaliero, Universitaria Pisana","startDate":"2014-01-01","conditions":"Stem Cell Transplant Complications","enrollment":20},{"nctId":"NCT01500382","phase":"PHASE1","title":"A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-02-27","conditions":"Overactive Bladder, Overactive Urinary Bladder","enrollment":4},{"nctId":"NCT03021590","phase":"PHASE4","title":"Comparison Efficacy of 14-day Concomitant Therapy:Clarithromycin vs.Levofloxacin in Eradication of H.Pylori","status":"WITHDRAWN","sponsor":"Damascus Hospital","startDate":"2017-06-01","conditions":"Helicobacter Pylori Gastrointestinal Tract Infection","enrollment":""},{"nctId":"NCT03395249","phase":"PHASE1","title":"Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2017-10-20","conditions":"Healthy Volunteers","enrollment":124},{"nctId":"NCT02166476","phase":"PHASE3","title":"Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2014-11-20","conditions":"Urinary Tract Infection Complicated, Acute Pyelonephritis","enrollment":550},{"nctId":"NCT01537250","phase":"PHASE2","title":"Phase II Clinical Study to Assess the Efficacy and Safety of Nemonoxacin Malate in Treating Adult Patients With Community-acquired Pneumonia (CAP)","status":"COMPLETED","sponsor":"TaiGen Biotechnology Co., Ltd.","startDate":"2009-08","conditions":"Community-acquired Pneumonia","enrollment":192},{"nctId":"NCT03391440","phase":"PHASE4","title":"A Trial to Assess the Efficacy and Safety of Morinidazole in Women With Pelvic Inflammatory Disease","status":"UNKNOWN","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2016-09","conditions":"Pelvic Inflammatory Disease","enrollment":469},{"nctId":"NCT03178292","phase":"NA","title":"Conventional Antibiotic Prophylaxis Versus Add-On 5 Days Levofloxacin Before Percutaneous Nephrolithotomy","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2017-06-15","conditions":"Percutaneous Nephrolithotomy, Infection, Sepsis","enrollment":300},{"nctId":"NCT00169585","phase":"PHASE3","title":"Levofloxacin For The Management Of Patients With Abnormal Prostate Specific Antigen (PSA)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"Prostatic Hyperplasia, Prostatitis","enrollment":240},{"nctId":"NCT02693574","phase":"PHASE4","title":"Comparison Efficacy of 14-day Triple Therapy: Clarithromycin vs. Levofloxacin on Eradication of H. Pylori","status":"UNKNOWN","sponsor":"Damascus Hospital","startDate":"2015-12-01","conditions":"Helicobacter Pylori Gastrointestinal Tract Infection","enrollment":74},{"nctId":"NCT00602589","phase":"PHASE1","title":"A Study to Evaluate the Bioequivalence of an Oral Suspension Formulation, an Oral Solution Formulation, and the Marketed Tablet Formulation of Levofloxacin in Healthy Subjects","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2002-10","conditions":"Healthy","enrollment":72},{"nctId":"NCT02726269","phase":"PHASE3","title":"Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.","status":"COMPLETED","sponsor":"Asofarma de México S.A de C.V.","startDate":"2012-06","conditions":"Helicobacter Pylori Gastritis","enrollment":230},{"nctId":"NCT02711943","phase":"","title":"Non Interventional Study of Levofloxacin in Chronic Prostatitis","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2013-07","conditions":"Chronic Prostatitis","enrollment":500},{"nctId":"NCT00002850","phase":"PHASE3","title":"Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy","status":"COMPLETED","sponsor":"Gary Morrow","startDate":"1997-03","conditions":"Infection, Multiple Myeloma","enrollment":212},{"nctId":"NCT02352701","phase":"","title":"Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori","status":"COMPLETED","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2012-12","conditions":"Helicobacter Infections","enrollment":320},{"nctId":"NCT02439632","phase":"PHASE3","title":"A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Uncomplicated Lower Urinary Tract Infection With Levofloxacin Hydrochloride Tablet as Active Control","status":"COMPLETED","sponsor":"Lee's Pharmaceutical Limited","startDate":"2014-02","conditions":"Acute Lower Urinary Tract Infection","enrollment":216},{"nctId":"NCT02157571","phase":"PHASE3","title":"A Multi-center, Randomized, Double-blind, Double-dummy Clinical Study to Evaluate the Safety and Efficacy of Prulifloxacin Film-coated Tablet for the Treatment of Acute Exacerbations of Chronic Bronchitis With Levofloxacin Hydrochloride Tablet as Active Control","status":"UNKNOWN","sponsor":"Lee's Pharmaceutical Limited","startDate":"2013-06","conditions":"Acute Exacerbations of Chronic Bronchitis","enrollment":360},{"nctId":"NCT02094703","phase":"PHASE4","title":"The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females","status":"UNKNOWN","sponsor":"Dr Cipto Mangunkusumo General Hospital","startDate":"2013-04","conditions":"Urinary Tract Infection","enrollment":126},{"nctId":"NCT00906048","phase":"PHASE3","title":"LEVOS - Levofloxacin and Rifampicin Therapy in the Treatment of OsteoArticular Prothethic Infection","status":"TERMINATED","sponsor":"Sanofi","startDate":"2009-04","conditions":"Infection","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Levofloxacin oral tablets","genericName":"Levofloxacin oral tablets","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Acute bacterial exacerbation of chronic bronchitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}